10x Genomics (TXG) Gross Profit (2018 - 2026)

10x Genomics has disclosed Gross Profit across 9 years of filings, most recently posting $106.2 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $106.2 million, up 0.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $444.6 million (up 4.12% YoY), and the FY2025 annual result was $443.9 million, up 7.09% from the prior year.
• Gross Profit came in at $106.2 million for Q1 2026 at 10x Genomics, down from $113.0 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $125.1 million in Q2 2025 to a low of $86.9 million in Q2 2022.
• The 5-year median for Gross Profit is $104.2 million (2024), against an average of $104.1 million.
• Across the five-year window, Gross Profit retreated 21.66% in 2022 and advanced 20.02% in 2025, its largest moves.
• 10x Genomics' Gross Profit stood at $119.4 million in 2022, then declined by 3.03% to $115.8 million in 2023, then dropped by 4.17% to $111.0 million in 2024, then increased by 1.88% to $113.0 million in 2025, then slipped by 6.07% to $106.2 million in 2026.
• The last three Gross Profit figures came in at $106.2 million (Q1 2026), $113.0 million (Q4 2025), and $100.3 million (Q3 2025), per Business Quant data.